SynAct Pharma

• Structured equity financing of 3,750,000 new shares generating gross proceeds of SEK 60.5m with 3,375,000 warrants providing the opportunity to raise an additional SEK 59.9m for SynAct Pharma
• The attached warrants are priced at a 10% premium to the subscription price of the directed share issue and can be exercised until 13 October 2025
• The transaction was fully subscribed by a subsidiary of Heights Capital Management, Inc. 
• SynAct Pharma intends to use the proceeds for: (i) continued development of the Company’s primary drug candidate resomelagon through proof-of-concept Phase II clinical studies; (ii) development of the TXP portfolio; and (iii) general corporate purposes 
• This transaction marks Van Lanschot Kempen’s fifth with SynAct Pharma as it demonstrates the versatility to assist a repeat client with tailor-made financing solutions to best meet its current needs

SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity in autoimmune and inflammatory diseases to help patients achieve immune balance and overcome their inflammation. 

In the last twelve months, Van Lanschot Kempen has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

• Lead Manager in the USD 173 million Capital Increase by Merus 
• Manager in the USD 1.3 billion Capital Increase by argenx
• Joint Bookrunner in the SEK 500 million Capital Increase by Vicore Pharma
• Financial Adviser to NewAmsterdam Pharma in the USD 182 million secondary sell-down by existing investors 
• Joint Global Coordinator & Joint Bookrunner in the EUR 25 million Capital Increase by Vivoryon Therapeutics
• Joint Global Coordinator & Joint Bookrunner in the EUR 16 million Capital Increase by Sequana Medical
• Lead Manager in the DKK 1.5 billion Capital Increase by Zealand Pharma
• Capital Markets Advisor & Placement Agent in the merger between European Biotech Acquisition Corp. and Oculis SA and the connected USD 91 million PIPE
• Lead Manager in the USD 250 million Capital Increase by CureVac
• Sole Financial Adviser to GenSight Biologics in securing a EUR 12 million credit facility from Heights Capital Management
• Joint Global Coordinator and Joint Bookrunner in the SEK 416 million Capital Increase by Hansa Biopharma
• Sole Financial Adviser in SynAct Pharma’s acquisition of TXP Pharma and Joint Global Coordinator & Joint Bookrunner in SynAct Pharma’s SEK 80 million PIPE
• Joint Bookrunner in the SEK 200 million Capital Increase by Vicore Pharma
• Joint Global Bookrunner in the SEK 148 million Fully Guaranteed Rights Issue by Biovica
• Sole Financial Adviser to GenSight Biologics in securing a EUR 35 million credit facility from the European Investment Bank
• Joint Global Coordinator & Joint Bookrunner in the SEK 170 million Capital Increase by Xbrane Biopharma
• Co-Lead Manager in the DKK 786 million Capital Increase by Zealand Pharma